Diabetes Mellitus, Type 2 Clinical Trial
Official title:
The Effect Of Aerobic Exercise On Bladder Function And Lower Urinary Tract Symptoms In Women Who Has Diabetes Mellitus With Lower Urinary Tract Symptoms
Verified date | March 2024 |
Source | Gaziantep Islam Science and Technology University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to investigate the effect of aerobic exercise (AE) on bladder functions and urinary system symptoms in women diagnosed with Diabetes Mellitus (DM) and suffered from Lower Urinary Tract Symptoms (LUTS). In the study, 44 individuals (35-55 age) were divided into two groups: Aerobic Exercise (AE) (n=22) and Control Group (n=22) by simple random method. The main questions it aims to answer are: - Is aerobic exercise effective on bladder functions in women diagnosed with Diabetes Mellitus and suffered from Lower Urinary Tract Symptoms? - Is aerobic exercise effective on urinary tract symptoms in women diagnosed with Diabetes Mellitus and suffered from Lower Urinary Tract Symptoms? - Is aerobic exercise effective on quality of life in women diagnosed with Diabetes Mellitus and suffered from Lower Urinary Tract Symptoms? Intervention/treatment - Control group individuals will be given a behavioral treatment program. - Submaximal aerobic exercise training will be given to the AE group in addition to the behavioral treatment program.
Status | Completed |
Enrollment | 44 |
Est. completion date | March 1, 2024 |
Est. primary completion date | March 1, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 35 Years to 55 Years |
Eligibility | Inclusion Criteria: - Women between the ages of 35-55, - Individuals who volunteer to participate in the study, - Those diagnosed with Type II diabetes for 5 years or more and those diagnosed with LUTS Exclusion Criteria: - Stage 2 and more advanced pelvic organ prolapse, - Urinary tract infection, - Has had previous surgery for urinary incontinence and pelvic organ prolapse, - Diagnosis of Cerebro Vascular Event (CVE) and dementia, - Using A-blockers, antimuscarinics, antidepressants, diuretics and antihistamines, - Individuals in menopause. |
Country | Name | City | State |
---|---|---|---|
Turkey | Hasan Kalyoncu University | Gaziantep |
Lead Sponsor | Collaborator |
---|---|
Gaziantep Islam Science and Technology University | Hasan Kalyoncu University, University of Gaziantep |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bladder Compliance | Bladder compliance will be evaluated by urodynamics. With urodynamic evaluations, pathologies of the lower urinary system can be diagnosed and classified. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic compliance (ml/cmH2O) will be recorded. | 10 minutes (Change from Baseline at 12 weeks) | |
Primary | Bladder Sensation | Bladder sensation will be evaluated by urodynamics. With urodynamic evaluations, pathologies of the lower urinary system can be diagnosed and classified. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic sensation (ml) will be recorded. | 10 minutes (Change from Baseline at 12 weeks) | |
Secondary | Voiding Volume | Voiding volume will be evaluated by urodynamics. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic Voiding volume (ml) will be recorded. | 10 minutes (Change from Baseline at 12 weeks) | |
Secondary | Voiding Time | Voiding time will be evaluated by urodynamics. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic Voiding time (sec) will be recorded. | 10 minutes (Change from Baseline at 12 weeks) | |
Secondary | Maximum Bladder Capacity | Maximum bladder capacity will be evaluated by urodynamics. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic Maximum bladder capacity (ml) will be recorded. | 10 minutes (Change from Baseline at 12 weeks) | |
Secondary | Urine Maximum Flow Rate | Urine maximum flow rate will be evaluated by urodynamics. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic Maximum flow rate (ml/s) will be recorded. | 10 minutes (Change from Baseline at 12 weeks) | |
Secondary | Bladder Residual Volume | Bladder residual volume rate will be evaluated by urodynamics. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic Residual volume (cc) will be recorded. | 10 minutes (Change from Baseline at 12 weeks) | |
Secondary | Ultrasonography (USG) evaluation | Ultrasonography will be performed by the doctor using the measured thickest part of the bladder wall as reference. The wall thickness of the bladder (mm) will be noted when the bladder is empty and full. USG is a non-invasive imaging method that physicians routinely use to evaluate the urinary system. | 10 minutes (Change from Baseline at 12 weeks) | |
Secondary | Bladder Diary | 48-hour bladder diary will be taken. The average of daily urination frequency numbers and daily fluid consumption amounts will be taken. | Change from Baseline at 12 weeks | |
Secondary | King's Health Questionnaire (KHQ) | It will be used to evaluate urinary system symptom severity and quality of life related to urinary system symptoms.The KHQ scale consists of two parts and 32 items. In the first part, there are two single-item questions about general health and quality of life. Again, in the first part, it consists of seven subheadings consisting of multiple items, including the individual's roles in daily life, physical condition, social situation, personal relationships, emotional problems, sleep/energy disorders, and violence measurements, and consists of 21 questions. The second part is a scale consisting of 11 questions that questions the presence of lower urinary tract symptoms and the severity of symptoms.Scoring on the Symptom Severity Scale ranges from 0 points (best) to 30 points (worst). In other KHQ subheadings, the scale scoring is 0 points (best) -100 points (worst). An increase in the score obtained from KHQ indicates a decrease in the quality of life. | Change from Baseline at 12 weeks | |
Secondary | Bristol Female Lower Urinary System Symptom Index (BFLUSSI) | It will be used to evaluate the Quality of Life Due to Lower Urinary System Symptoms.This scale includes storage functions (questions 1-4), excretory functions (questions 5-7), urinary incontinence (questions 8-12), sexual life (questions 13-14) and quality of life (questions 15-19). It consists of five sections with subheadings. The highest score that can be obtained from the survey is 71, while the lowest score is 0. A high score from the survey indicates that the severity of LUTS is high and sexual functions and quality of life are negatively affected. |
Change from Baseline at 12 weeks | |
Secondary | HbA1c | HbA1c (blood glucose level) will be noted as a result of the blood evaluations taken by the clinician. | Change from Baseline at 12 weeks | |
Secondary | Patient Information Form | Patient information such as sociodemographic (age (year), occupation (employed/unemployed), education (literate/primary school/high school/university/graduate school), marital status (married/single), number of births (n), type of delivery (vaginal/caesarean section) and physical (height (m), weight (kg), BMI (kg/m2),constipation (, type 2 DM duration (year)) will be noted. Personal habits (liquid consumption habits (ml), number of urinations per day (n)) will be noted. | Change from Baseline at 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |